INT3041

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.56
First Reported 1977
Last Reported 2010
Negated 0
Speculated 1
Reported most in Abstract
Documents 34
Total Number 35
Disease Relevance 21.11
Pain Relevance 6.49

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endoplasmic reticulum (MIA3)
Anatomy Link Frequency
plasma 14
blood 2
B-cell 2
erythrocytes 1
cleavage 1
MIA3 (Homo sapiens)
Pain Link Frequency Relevance Heat
Pain score 3 99.46 Very High Very High Very High
Opioid 10 99.40 Very High Very High Very High
Endogenous opioid 3 98.80 Very High Very High Very High
anesthesia 2 98.80 Very High Very High Very High
Chronic pancreatitis 26 98.40 Very High Very High Very High
narcan 7 98.18 Very High Very High Very High
qutenza 7 98.08 Very High Very High Very High
antagonist 5 98.00 Very High Very High Very High
tolerance 31 97.96 Very High Very High Very High
Pain 3 97.96 Very High Very High Very High
Disease Link Frequency Relevance Heat
Uremia 3 99.64 Very High Very High Very High
Obesity 50 99.54 Very High Very High Very High
Hypoglycemia 47 99.40 Very High Very High Very High
Pain 6 99.34 Very High Very High Very High
Diabetes Mellitus 437 99.08 Very High Very High Very High
Atherosclerosis 43 98.68 Very High Very High Very High
Pancreatitis 41 98.66 Very High Very High Very High
Heart Rate Under Development 2 98.40 Very High Very High Very High
Insulin Resistance 37 98.36 Very High Very High Very High
Adenoma 10 98.28 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Administration of synthetic human corticotropin-releasing factor (hCRF, 2 micrograms/kg body weight) during simultaneous application of the opioid antagonist naloxone (1.6 mg i.v. bolus, followed by an infusion at a rate of 1.2 mg/h) produced a significant increase in plasma C-peptide levels of six male Type 2 diabetic patients which even exceeded the postprandial values.
Positive_regulation (increase) of C-peptide in plasma associated with body weight, diabetes mellitus, antagonist, narcan and opioid
1) Confidence 0.56 Published 1988 Journal Klin. Wochenschr. Section Abstract Doc Link 2836651 Disease Relevance 0.27 Pain Relevance 0.34
The patient had normal levels of plasma carcinoembryonic antigen, carbohydrate antigen 19-9, alpha-fetoprotein, but an increase in plasma levels of insulin and C-peptide.
Positive_regulation (increase) of C-peptide in plasma
2) Confidence 0.35 Published 2001 Journal J. Gastroenterol. Hepatol. Section Abstract Doc Link 11206307 Disease Relevance 0.91 Pain Relevance 0.13
In the same subjects, beta-endorphin produced elevations of plasma glucose, insulin, C-peptide, and glucagon.
Positive_regulation (elevations) of C-peptide in plasma
3) Confidence 0.26 Published 1988 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 2969000 Disease Relevance 0.26 Pain Relevance 0
In both obese and post-obese subjects, the infusion of beta-endorphin caused significant increases in peripheral plasma glucose, insulin, C-peptide and glucagon concentrations.
Positive_regulation (increases) of C-peptide in plasma associated with obesity
4) Confidence 0.26 Published 1991 Journal Acta Endocrinol. Section Abstract Doc Link 2003375 Disease Relevance 1.41 Pain Relevance 0.05
The plasma levels of insulin and C-peptide increased from 90 to 165 min after glucose loading but there were no significant difference between the results obtained without and with capsaicin administration.
Positive_regulation (increased) of C-peptide in plasma associated with qutenza
5) Confidence 0.19 Published 2006 Journal Eur. J. Pharmacol. Section Abstract Doc Link 16612838 Disease Relevance 0 Pain Relevance 0.56
The infusion of synthetic human beta-endorphin (4.5 ng/kg/min) produced the following: (1) in normal-weight subjects, no significant change of plasma glucose and pancreatic hormones (insulin, C-peptide, and glucagon), a significant plasma free fatty acids (FFA) increase, and a suppression of glycerol plasma levels; (2) in obese subjects, significant increases of glucose, insulin, C-peptide, and glucagon, a progressive decline of circulating FFA, and no change in glycerol plasma levels.
Positive_regulation (increases) of C-peptide in plasma associated with obesity
6) Confidence 0.17 Published 1992 Journal Metab. Clin. Exp. Section Abstract Doc Link 1736041 Disease Relevance 0.35 Pain Relevance 0.15
No patients were cured of diabetes, although transient evidence of islet function--increase in serum or urinary C-peptide levels or decrease in exogenous insulin requirements--occurred in some.
Positive_regulation (increase) of C-peptide associated with diabetes mellitus
7) Confidence 0.11 Published 1980 Journal Diabetes Section Abstract Doc Link 6766413 Disease Relevance 0.45 Pain Relevance 0.14
The magnitude of the response following C-peptide replacement treatment occurred completely
Positive_regulation (following) of C-peptide
8) Confidence 0.11 Published 2008 Journal Experimental Diabetes Research Section Body Doc Link PMC2266809 Disease Relevance 0.75 Pain Relevance 0.03
secretion ceases totally, those patients who retain a low-endogenous C-peptide
Positive_regulation (endogenous) of C-peptide
9) Confidence 0.11 Published 2008 Journal Experimental Diabetes Research Section Body Doc Link PMC2266809 Disease Relevance 0.40 Pain Relevance 0.03
All patients developed moderate tachycardia and exhibited metabolic effects following salbutamol infusion, implying marked increases in plasma levels of insulin, C-peptide, glucose and lactate.
Positive_regulation (increases) of C-peptide in plasma associated with heart rate under development
10) Confidence 0.09 Published 1977 Journal Acta Obstet Gynecol Scand Section Abstract Doc Link 602717 Disease Relevance 0.37 Pain Relevance 0.17
In the pre-resection phase, only two cases revealed hypoglycemia and required dextrose infusion to correct hypoglycemia and reach euglycemic levels, whereas all the patients showed elevated insulin and C-peptide levels.
Positive_regulation (elevated) of C-peptide associated with hypoglycemia
11) Confidence 0.09 Published 1985 Journal Ital J Surg Sci Section Abstract Doc Link 2995275 Disease Relevance 0.69 Pain Relevance 0.10
In all patients this manoeuvre caused an increase of insulin and C-peptide levels and in two cases a slight decrease of blood glucose levels.
Positive_regulation (increase) of C-peptide in blood
12) Confidence 0.09 Published 1985 Journal Ital J Surg Sci Section Abstract Doc Link 2995275 Disease Relevance 0.78 Pain Relevance 0.09
None had a measurable basal level of either plasma C-peptide or a C-peptide response to i.v. glucagon.
Positive_regulation (level) of C-peptide in plasma
13) Confidence 0.07 Published 1981 Journal Diabetes Section Abstract Doc Link 6115786 Disease Relevance 0.33 Pain Relevance 0.29
Insulin and C-peptide levels were high during the hypoglycemic episode and returned to normal after discontinuation of gabapentin.
Positive_regulation (high) of C-peptide associated with gabapentin
14) Confidence 0.06 Published 2003 Journal Am. J. Kidney Dis. Section Abstract Doc Link 14655224 Disease Relevance 1.00 Pain Relevance 0.53
Typically, these patients show increased levels of C-peptide and over the last years various groups examined the effect of C-peptide in vascular cells as well as its potential role in lesion development.
Positive_regulation (increased) of C-peptide
15) Confidence 0.04 Published 2008 Journal Experimental Diabetes Research Section Abstract Doc Link PMC2288642 Disease Relevance 0.58 Pain Relevance 0.03
temporarily demonstrate elevated levels of the proinsulin cleavage product C-peptide.
Positive_regulation (elevated) of C-peptide in cleavage
16) Confidence 0.04 Published 2008 Journal Experimental Diabetes Research Section Body Doc Link PMC2288642 Disease Relevance 0.86 Pain Relevance 0.04
beneficial while an increase in C-peptide levels in patients with insulin
Positive_regulation (increase) of C-peptide
17) Confidence 0.04 Published 2008 Journal Experimental Diabetes Research Section Body Doc Link PMC2288642 Disease Relevance 1.31 Pain Relevance 0
The DCCT showed that intensive insulin therapy helps sustain endogenous insulin secretion (with stimulated C-peptide levels above the clinically relevant value of 0.2 pmol/ml), suggesting that continuous insulin administration and its glucose-lowering effect is potentially beneficial for B-cell preservation [56].
Positive_regulation (stimulated) of C-peptide in B-cell
18) Confidence 0.04 Published 2008 Journal Diabetic Medicine Section Body Doc Link PMC2701557 Disease Relevance 0.56 Pain Relevance 0.04
The Diabetes Control and Complications Trial (DCCT) established support for the relationship between residual B-cell function and glucose control as individuals who had stimulated C-peptide levels > 0.2 pmol/ml had improved responses to treatment and outcomes [9–12].
Positive_regulation (stimulated) of C-peptide in B-cell associated with diabetes mellitus
19) Confidence 0.04 Published 2008 Journal Diabetic Medicine Section Body Doc Link PMC2701557 Disease Relevance 0.73 Pain Relevance 0
Likewise, the report of a clinical trial in latent autoimmune diabetes in adults (LADA) patients using an alum-formulated recombinant human GAD65 showed promise, as it increased C-peptide levels and the purported Tregs subset in peripheral blood.
Positive_regulation (increased) of C-peptide in blood associated with diabetes mellitus
20) Confidence 0.03 Published 2008 Journal Diabetic Medicine Section Body Doc Link PMC2701557 Disease Relevance 0.42 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox